CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024.
CASI制药公司（纳斯达克股票代码：CASI），一家注册在开曼群岛的生物药企，专注于开发和商业化创新治疗方案和药品产品，宣布任命丹尼尔·朗医学博士为公司首席财务官兼高级副总裁，任期自2024年7月8日起生效。
Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform.
朗博士作为一名医学科学家、投资人和生物科技行业高管拥有超过30年的从业经验。他是加州旧金山大学的心脏科医生，之后在法拉隆资本担任20年的投资经理和RS投资价值集团的首席投资官。最近，他担任埃森诺斯NKt细胞治疗部门的总裁，并领导NKt细胞平台的临床开发。